Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group

被引：0
|
作者：
Smith, J. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Buyse, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Rastogi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Geyer, C., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Jacobs, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Patocskai, E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wolmark, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Columbia River Oncol Program, Portland, OR USA
[2] IDDI, Louvain, Belgium
[3] NSABP, Pittsburgh, PA USA
[4] UPCI, Magee Womens Hosp, Womens Canc Clin, Pittsburgh, PA USA
[5] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[6] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[7] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5
    Smith, John W., II
    Buyse, Marc E.
    Rastogi, Priya
    Geyer, Charles E., Jr.
    Jacobs, Samuel A.
    Patocskai, Erica J.
    Robidoux, Andre
    Conlin, Alison K.
    Ansari, Bilal
    Keogh, George P.
    Stella, Philip J.
    Gross, Howard M.
    Lord, Raymond S.
    Polikoff, Jonathan A.
    Mauquoi, Celine
    Mamounas, Eleftherios P.
    Swain, Sandra M.
    Wolmark, Norman
    CLINICAL BREAST CANCER, 2017, 17 (01) : 48 - +
  • [2] A multicenter phase II study of primary systemic therapy epirubicin/cyclophosphamide followed by docetaxel plus concurrent trastuzumab for HER2-positive advanced breast cancer.
    Saeki, T.
    Aogi, K.
    Nakamura, S.
    Kashiwaba, M.
    Sato, N.
    Masuda, N.
    Rai, Y.
    Ohno, S.
    Miyakoda, K.
    Ikeda, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab (HER TC) in HER2-Positive Early Stage Breast Cancer Patients.
    Jones, S.
    Collea, R.
    Paul, D.
    Oratz, R.
    Sedlacek, S.
    Favret, A. M.
    Gore, I. I.
    Lindquist, D. L.
    Holmes, F. A.
    Allison, M. A. K.
    Steinberg, M. S.
    Stokoe, C.
    Portillo, R. M.
    Crockett, M.
    Wang, Y.
    Asmar, L.
    Robert, N.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2011, 71
  • [4] Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Zhang, Guozhi
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yu, Qiao
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Liu, Jiangbo
    Zhang, Yi
    Jiang, Jun
    CANCER RESEARCH, 2023, 83 (05)
  • [5] Liposome-encapsulated doxorubicin plus cyclophosphamide followed by trastuzumab plus docetaxel as neoadjuvant therapy for HER2-positive breast cancer (BC): A multicenter single-arm phase II study
    Saracchini, Silvana
    Foltran, Luisa
    Sulfaro, Sandro
    Tuccia, Fausto
    Del Conte, Alessandro
    Bertolla, Manuella
    Bassini, Anna
    Micheli, Elvia
    Manente, Stefania
    Gusso, Giuseppina
    Baresic, Tania
    Tumoio, Salvatore
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Radiotherapy plus trastuzumab in the treatment of Her2-positive locally advanced breast cancer
    Belokhvostova, A.
    Ragulin, Y.
    ANNALS OF ONCOLOGY, 2015, 26
  • [7] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Mariani, Gabriella
    Fasolo, Angelica
    De Benedictis, Elena
    Gianni, Luca
    NATURE CLINICAL PRACTICE ONCOLOGY, 2009, 6 (02): : 93 - 104
  • [8] Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
    Gabriella Mariani
    Angelica Fasolo
    Elena De Benedictis
    Luca Gianni
    Nature Clinical Practice Oncology, 2009, 6 : 93 - 104
  • [9] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Katsuhiko Nakatsukasa
    Hiroshi Koyama
    Yoshimi Oouchi
    Seiichi Imanishi
    Naruhiko Mizuta
    Kouichi Sakaguchi
    Yoshifumi Fujita
    Aya Imai
    Akiko Okamoto
    Asako Hamaoka
    Mari Soushi
    Ikuya Fujiwara
    Tatsuya Kotani
    Takayuki Matsuda
    Kenichirou Fukuda
    Midori Morita
    Sadao Kawakami
    Yayoi Kadotani
    Eiichi Konishi
    Akio Yanagisawa
    Mariko Goto
    Kei Yamada
    Tetsuya Taguchi
    Breast Cancer, 2017, 24 : 92 - 97
  • [10] Docetaxel, cyclophosphamide, and trastuzumab as neoadjuvant chemotherapy for HER2-positive primary breast cancer
    Nakatsukasa, Katsuhiko
    Koyama, Hiroshi
    Oouchi, Yoshimi
    Imanishi, Seiichi
    Mizuta, Naruhiko
    Sakaguchi, Kouichi
    Fujita, Yoshifumi
    Imai, Aya
    Okamoto, Akiko
    Hamaoka, Asako
    Soushi, Mari
    Fujiwara, Ikuya
    Kotani, Tatsuya
    Matsuda, Takayuki
    Fukuda, Kenichirou
    Morita, Midori
    Kawakami, Sadao
    Kadotani, Yayoi
    Konishi, Eiichi
    Yanagisawa, Akio
    Goto, Mariko
    Yamada, Kei
    Taguchi, Tetsuya
    BREAST CANCER, 2017, 24 (01) : 92 - 97
12345